Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

Plain-language summary

This study examined the effect of Resveratrol on age-related insulin resistance and inflammation. It enrolled healthy non-smokers with a body mass index between 26 and 35. It was carried out in Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

Albert Einstein College of Medicine

Intervention

Resveratrol

Start date

3/1/2008

Estimated completion

9/15/2017

Countries

United States

Related genes

Locations

• The Bronx, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* BMI: 26-35
* Non-smoker
* Normal screening labs (CMC, chemistry, LFTs PT/PTT)
* No CAD
* Good IV access

Exclusion Criteria:

* High cholesterol
* \<4 week history of participation in another drug trial
* Severe hypertension
* Heart disease
* Liver disease of liver abnormalities
* Cerebrovascular disease, i.e. stroke
* CVD
* Seizures
* Bleeding disorders
* Muscle disease
* Cancer
* HIV
* Hepatitis (all types)
* Mentally disabled persons
* Pregnant women
* Allergies to Novocaine, Lidocaine, Benzocaine
* Subjects on the following medications:

  * Anticoagulant and antiplatelet drugs
  * Anti-epileptic drugs
  * Mexiletene
  * Quinidine
  * Cyclosporine
  * Tacrolimus
  * HIV protease inhibitors